Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
4.820
-0.040 (-0.82%)
At close: Aug 21, 2026, 4:00 PM EDT
4.860
+0.040 (0.83%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 76 employees as of December 31, 2025. The number of employees increased by 5 or 7.04% compared to the previous year.
Employees
76
Change (1Y)
5
Growth (1Y)
7.04%
Revenue / Employee
$398,961
Profits / Employee
-$410,303
Market Cap
82.80M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 5 | 7.04% |
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pelthos Therapeutics | 92 |
| ImmuCell | 73 |
| Elicio Therapeutics | 33 |
| NeurAxis | 24 |
| Gain Therapeutics | 21 |
| Cognition Therapeutics | 14 |
| MAIA Biotechnology | 13 |
| Rallybio | 7 |
VRCA News
- 3 days ago - Verrica Pharmaceuticals CEO buys $125.8K in common stock - TheFly
- 15 days ago - Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c) - TheFly
- 15 days ago - Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 15 days ago - Verrica Pharmaceuticals Earnings release: Q2 2026 - Filings
- 15 days ago - Verrica Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 23 days ago - Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire